Norman LaFrance, MD, CMO & Senior VP, and Melissa Moore, PhD, VP of Clinical Research for Plus Therapeutics Inc. PSTV were recently interviewed by Benzinga.
Plus Therapeutics is a clinical stage pharmaceutical company that has developed a radiotherapeutic platform with the potential to lengthen and improve the lives of adults and children with challenging cancers.
The company takes a unique approach in combining radiation particles with nanoliposomes and alginate microspheres; it hopes to target cancer more safely, precisely and effectively than other approaches in radiation therapy and oncology.
Watch the full interview here:
Featured photo by National Cancer Institute on Unsplash.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
